Holen Sie sich die Stockscreener-App
10.00
5.37%
0.51
Handel nachbörslich:
9.71
-0.29
-2.90%
Schlusskurs vom Vortag:
$9.49
Offen:
$9.82
24-Stunden-Volumen:
10.14M
Relative Volume:
4.07
Marktkapitalisierung:
$1.39B
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-2.551
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
+27.71%
1M Leistung:
+32.28%
6M Leistung:
+128.31%
1J Leistung:
+9.89%
1-Tages-Spanne:
$9.76
$10.94
1-Wochen-Bereich:
$7.26
$10.94
52-Wochen-Spanne:
$4.155
$10.94
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.00 | 1.32B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Vir Biotechnology Extends Reach with Astellas Collaboration on VIR-5500 - StocksToTrade
Vir Biotechnology leaps on news of Astellas collaboration - The Pharma Letter
Vir Biotechnology (VIR) Receives Maintained Overweight Rating Fr - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Vir Biotechnology plans $200 million stock offering - Investing.com India
Vir Biotechnology Announces Proposed Public Offering of Common Stock - BioSpace
A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update - Yahoo Finance
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,089 Shares of Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CEO Sells 19,039 Shares of Stock - MarketBeat
Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 2,089 Shares of Stock - MarketBeat
Aug Big Picture: Can Vir Biotechnology Inc be recession proofJuly 2025 Chart Watch & AI Based Trade Execution Alerts - baoquankhu1.vn
VIR: Needham Raises Vir Biotechnology's Price Target in New Anal - GuruFocus
Vir Biotechnology’s Call Highlights Astellas Deal, VIR-5500 Momentum - TipRanks
Vir Biotechnology launches $200M public stock offering - MSN
These Stocks Are Today’s Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More - Barron's
VIR Stock Offering Managed by Leading Financial Firms - GuruFocus
Astellas, Vir Biotechnology form partnership on prostate cancer drug By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week high at 9.88 USD By Investing.com - Investing.com South Africa
Vir Biotechnology plans $200 million stock offering By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) Stock Surges to 52-Week High on Astellas Deal and Strong Earnings - MEXC
This Small-Cap Biotech Stock Is Soaring 29%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - The Malaysian Reserve
Morgan Stanley Raises Price Target for VIR to $24 with Overweigh - GuruFocus
Vir Biotechnology: Up On Prostate Data And Astellas DealI'm (Long-Term) Bullish (VIR) - Seeking Alpha
These Analysts Boost Their Forecasts On Vir Biotechnology - Benzinga
Vir Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Astellas and Vir in $1.3B deal for CD3 T-cell engager - BioWorld MedTech
Vir Biotechnology, Inc. Q4 & Full Year 2025 Earnings: Revenue Hits $64.1M on Norgine Deal - Bayelsa Watch
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug - Barron's
VIR: Evercore ISI Group Raises Price Target to $18, Maintains Ou - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High After Earnings Beat - MarketBeat
Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN - Pharmaceutical Executive
Biotech and Big Tech Drive the Morning Narrative (2026-02-24) - Seeking Alpha
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday - Benzinga
Vir Biotechnology Secures New Collaboration and Revenue Surge - StocksToTrade
AMD, Hims & Hers, Home Depot, Kratos, Novo Nordisk, IBM, Keysight, Vir Biotechnology, and More Movers - Barron's
This Small-Cap Biotech Stock Is Soaring 26%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's
How a prostate cancer drug and a $1.7 billion deal landed at Vir BioSan Francisco Business Times - The Business Journals
Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500 - Contract Pharma
Vir Biotechnology stock hits 52-week high at 9.88 USD - Investing.com
Vir Biotechnology’s Strategic Moves Shake Up the Biotech Scene - timothysykes.com
Vir Biotechnology (VIR) Stock: Reaches 52-Week High as Three Big Catalysts Hit at Once - Blockonomi
This Small-Cap Biotech Stock Is Soaring 35%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's
Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED) - Benzinga
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Why Is Vir Biotechnology Stock Up Today? - TipRanks
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $18.00 - MarketBeat
Raymond James upgrades Vir Biotechnology stock rating on drug data - Investing.com Australia
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.52%
1.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):